The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Mayzent siponimod | Novartis Europharm Limited | Multiple Sclerosis, Relapsing-Remitting | 🇪🇺 EU 2020-01-13 | Order → |
| Clopidogrel / Acetylsalicylic acid Viatris (previously Clopidogrel / Acetylsalicylic acid Mylan) clopidogrel;acetylsalicylic acid Generic | Mylan Pharmaceuticals Limited | Acute Coronary Syndrome; Myocardial Infarction | 🇪🇺 EU 2020-01-09 | Order → |
| Deferasirox Accord deferasirox Generic | Accord Healthcare S.L.U. | Iron Overload; beta-Thalassemia | 🇪🇺 EU 2020-01-09 | Order → |
| Isturisa osilodrostat Orphan | Recordati Rare Diseases | Cushing Syndrome | 🇪🇺 EU 2020-01-09 | Order → |
| Tavlesse fostamatinib | Instituto Grifols S.A. | Thrombocytopenia | 🇪🇺 EU 2020-01-09 | Order → |
| Cegfila (previously Pegfilgrastim Mundipharma) pegfilgrastim Biosimilar | Mundipharma Corporation (Ireland) Limited | 🇪🇺 EU 2019-12-19 | Order → | |
| Spravato esketamine | Janssen-Cilag International NV | Depressive Disorder | 🇪🇺 EU 2019-12-18 | Order → |
| Baqsimi glucagon | Amphastar France Pharmaceuticals | Diabetes Mellitus | 🇪🇺 EU 2019-12-16 | Order → |
| Quofenix delafloxacin | A. Menarini Industrie Farmaceutiche Riunite s.r.l. | Community-Acquired Infections | 🇪🇺 EU 2019-12-16 | Order → |
| Rinvoq upadacitinib | AbbVie Deutschland GmbH & Co. KG | Arthritis, Rheumatoid; Arthritis, Psoriatic; Axial Spondyloarthritis; Spondylitis, Ankylosing; Giant Cell Arteritis; Dermatitis, Atopic; Colitis, Ulcerative; Cr | 🇪🇺 EU 2019-12-16 | Order → |
| Evenity romosozumab | UCB Pharma S.A. | Osteoporosis | 🇪🇺 EU 2019-12-09 | Order → |
| Rhokiinsa netarsudil Additional monitoring | Santen Oy | Glaucoma, Open-Angle; Ocular Hypertension | 🇪🇺 EU 2019-11-19 | Order → |
| Arsenic trioxide Accord arsenic trioxide Generic | Accord Healthcare S.L.U. | Leukemia, Promyelocytic, Acute | 🇪🇺 EU 2019-11-14 | Order → |
| Bortezomib Fresenius Kabi bortezomib Generic | Fresenius Kabi Deutschland GmbH | Multiple Myeloma | 🇪🇺 EU 2019-11-14 | Order → |
| Ivozall clofarabine Generic | ORPHELIA Pharma | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 🇪🇺 EU 2019-11-14 | Order → |
| Senstend lidocaine;prilocaine | Plethora Pharma Solutions Limited | Premature Ejaculation | 🇪🇺 EU 2019-11-14 | Order → |
| Ervebo Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live) PRIME | Merck Sharp & Dohme B.V. | Hemorrhagic Fever, Ebola | 🇪🇺 EU 2019-11-11 | Order → |
| Qtrilmet metformin hydrochloride;saxagliptin;dapagliflozin | AstraZeneca AB | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2019-11-11 | Order → |
| Xospata gilteritinib Orphan | Astellas Pharma Europe B.V. | Leukemia, Myeloid, Acute | 🇪🇺 EU 2019-10-24 | Order → |
| Nuceiva botulinum toxin type a Additional monitoring | Evolus Pharma B.V. | Skin Aging | 🇪🇺 EU 2019-09-27 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.